Trial Profile

A phase I/II trial assessing new intranasal corona vaccine

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2022 New trial record
05 Jan 2022 According to Intravacc media release, this study is led by Dr Leo Visser of the Infectious Diseases Department of the LUMC and is expected to start at the end of 2022 with first study data expected in the first half of 2023.
05 Jan 2022 According to Intravacc media release, the company announced a partnership with Dutch Leiden University Medical Center (LUMC) to develop and evaluate a new nasal spray corona vaccine in this trial, financing of this study is made possible in part by the Top Consortium for Knowledge and Innovation (TKI) of Health Holland, part of the Dutch top sector Life Sciences & Health.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com